{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:51:03Z","timestamp":1783421463445,"version":"3.54.6"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>This review explores the management of persistent methicillin-susceptible Staphylococcus aureus bacteremia (SAB), emphasizing the importance of timely intervention due to SAB\u2019s association with metastatic dissemination, relapse, and mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The literature analysis first delves into risk factors for persistent SAB, highlighting the need for effective treatment strategies. The subsequent focus is on combination strategies for persistent SAB. Daptomycin, ertapenem, ceftaroline, fosfomycin, rifampin, and gentamicin are explored as adjuncts to cefazolin or antistaphylococcal penicillins. Daptomycin combination therapy is assessed through in vivo and clinical studies, indicating potential benefits, especially with higher-risk sources of infection. Ertapenem combination therapy has been demonstrated to have a synergistic effect with cefazolin, presenting a viable salvage option. Rifampin\u2019s ability to penetrate biofilm is examined, with discussion of inconclusive evidence on mortality benefits. The review also considers stewardship implications, discussing concerns such as resistance emergence, adverse events, and increased costs associated with combination therapy. Mathematical models suggest combination therapy as an effective approach to prevent resistance. Adverse events vary with each combination, and duration of therapy remains diverse across studies in the absence of well-established dosing guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The review provides a thorough exploration of the literature on treatment of persistent SAB, underscoring the need for evidence-based guidelines, further studies, and clinical judgment in tailoring treatment strategies. The multifaceted analysis contributes valuable insights for clinicians managing this challenging condition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae252","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T08:25:14Z","timestamp":1725524714000},"page":"150-163","source":"Crossref","is-referenced-by-count":3,"title":["Exploring combination treatment options for persistent methicillin-susceptible <i>Staphylococcus aureus<\/i> bacteremia"],"prefix":"10.1093","volume":"82","author":[{"given":"Hiba","family":"Al Shaikhli","sequence":"first","affiliation":[{"name":"University of Mississippi Medical Center , Jackson, MS,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronda L","family":"Akins","sequence":"additional","affiliation":[{"name":"Methodist Charlton Medical Center , Dallas, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla R","family":"Stover","sequence":"additional","affiliation":[{"name":"University of Mississippi , Jackson, MS,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-3111","authenticated-orcid":false,"given":"Katie E","family":"Barber","sequence":"additional","affiliation":[{"name":"University of Mississippi , Jackson, MS,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"issue":"3","key":"2025021005563097200_CIT0001","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"2025021005563097200_CIT0002","doi-asserted-by":"publisher","first-page":"e25460","DOI":"10.7759\/cureus.25460","article-title":"Incidence trends and epidemiology of Staphylococcus aureus bacteremia: a systematic review of population-based studies","volume":"14","author":"Hindy","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"2025021005563097200_CIT0003","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2025021005563097200_CIT0004","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"2025021005563097200_CIT0005","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/archinte.167.17.1861","article-title":"Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes","volume":"167","author":"Hawkins","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1","key":"2025021005563097200_CIT0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/00365540500372846","article-title":"Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome","volume":"38","author":"Khatib","year":"2006","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"2025021005563097200_CIT0007","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1086\/423145","article-title":"Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbiocidal protein","volume":"190","author":"Fowler","year":"2004","journal-title":"J Infect Dis"},{"issue":"4","key":"2025021005563097200_CIT0008","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025021005563097200_CIT0009","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/01.md.0000091185.93122.40","article-title":"A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"suppl 3","key":"2025021005563097200_CIT0010","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1469-0691.2000.tb02038.x","article-title":"The final goal: penicillin-binding proteins and the target of cephalosporins","volume":"6","author":"Fontana","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"2025021005563097200_CIT0011","article-title":"Chapter 7 - Antimicrobial therapy in infective endocarditis","volume-title":"Infective Endocarditis: A Multidisciplinary Approach","author":"Chiappelli","year":"2022"},{"key":"2025021005563097200_CIT0012","author":"Nafcillin","year":"2007"},{"key":"2025021005563097200_CIT0013","author":"Oxacillin","year":"2015"},{"issue":"suppl 3","key":"2025021005563097200_CIT0014","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025021005563097200_CIT0015","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025021005563097200_CIT0016","doi-asserted-by":"publisher","first-page":"ofab071","DOI":"10.1093\/ofid\/ofab071","article-title":"Antistaphylococcal penicillin vs cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus spinal epidural abscesses","volume":"8","author":"Corsini Campioli","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025021005563097200_CIT0017","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis","author":"Liu","year":"2011"},{"issue":"4","key":"2025021005563097200_CIT0018","doi-asserted-by":"publisher","first-page":"e0066922","DOI":"10.1128\/mbio.00669-22","article-title":"Penicillin-binding protein 1 (PBP1) of Staphylococcus aureus has multiple essential functions in cell division","volume":"13","author":"Wacnik","year":"2022","journal-title":"mBio"},{"issue":"10","key":"2025021005563097200_CIT0019","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1128\/AAC.00594-13","article-title":"\u03b2-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus","volume":"57","author":"Berti","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025021005563097200_CIT0020","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1128\/AAC.46.9.2878-2884.2002","article-title":"Effects of neutrophils on cefazolin activity and penicillin-binding proteins in Staphylococcus aureus abscesses","volume":"46","author":"Bamberger","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025021005563097200_CIT0021","doi-asserted-by":"publisher","first-page":"e00863","DOI":"10.1128\/AAC.00863-17","article-title":"\u03b2-Lactam antibiotics with a high affinity for PBP2 act synergistically with the FtsZ-Targeting agent TXA707 against methicillin-resistant Staphylococcus aureus","volume":"61","author":"Ferrer-Gonz\u00e1lez","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2025021005563097200_CIT0022","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025021005563097200_CIT0023","author":"Cubicin","year":"2016"},{"issue":"2","key":"2025021005563097200_CIT0024","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2025021005563097200_CIT0025","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/AAC.00502-12","article-title":"Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics","volume":"56","author":"Berti","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2025021005563097200_CIT0026","doi-asserted-by":"publisher","first-page":"e0164921","DOI":"10.1128\/AAC.01649-21","article-title":"Synergy mechanisms of daptomycin-fosfomycin combinations in daptomycin-susceptible and -resistant methicillin-resistant Staphylococcus aureus: in vitro, ex vivo, and in vivo metrics","volume":"66","author":"Mishra","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2025021005563097200_CIT0027","doi-asserted-by":"publisher","first-page":"ofac159","DOI":"10.1093\/ofid\/ofac159","article-title":"Potent activity of ertapenem plus cefazolin within staphylococcal biofilms: a contributing factor in the treatment of methicillin-susceptible Staphylococcus aureus endocarditis","volume":"9","author":"Gilbertie","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2025021005563097200_CIT0028","first-page":"252","article-title":"In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus","volume":"19","author":"Sahuquillo Arce","year":"2006","journal-title":"Rev Esp Quimioter"},{"key":"2025021005563097200_CIT0029","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fphar.2017.00553","article-title":"Synergistic effect of pleuromutilins with other antimicrobial agents against Staphylococcus aureus in vitro and in an experimental Galleria mellonella model","volume":"8","author":"Dong","year":"2017","journal-title":"Front Pharmacol"},{"issue":"11","key":"2025021005563097200_CIT0030","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1128\/AAC.01192-16","article-title":"Cefazolin and ertapenem, a synergistic combination used to clear persistent Staphylococcus aureus bacteremia","volume":"60","author":"Sakoulas","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2025021005563097200_CIT0031","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/cid\/ciz995","article-title":"Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible Staphylococcus aureus bacteremia","volume":"71","author":"Ulloa","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025021005563097200_CIT0032","doi-asserted-by":"publisher","first-page":"dlab148","DOI":"10.1093\/jacamr\/dlab148","article-title":"Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series","volume":"3","author":"El-Dalati","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"8","key":"2025021005563097200_CIT0033","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Mir\u00f3","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2025021005563097200_CIT0034","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2025021005563097200_CIT0035","doi-asserted-by":"publisher","first-page":"685807","DOI":"10.3389\/fphar.2021.685807","article-title":"Synergistic effect of cefazolin plus fosfomycin against Staphylococcus aureus in vitro and in vivo in an experimental Galleria mellonella model","volume":"12","author":"Kussmann","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"2025021005563097200_CIT0036","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jac\/dkr019","article-title":"Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus","volume":"66","author":"Jacqueline","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"2025021005563097200_CIT0037","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1093\/jac\/dkaa354","article-title":"Hospital Cl\u00ednic Endocarditis Study Group. Cloxacillin or fosfomycin plus daptomycin combinations are more active than cloxacillin monotherapy or combined with gentamicin against MSSA in a rabbit model of experimental endocarditis","volume":"75","author":"Garc\u00eda-de-la-M\u00e0ria","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2025021005563097200_CIT0038","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41591-023-02569-0","article-title":"Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial","volume":"29","author":"Grillo","year":"2023","journal-title":"Nat Med"},{"key":"2025021005563097200_CIT0039","doi-asserted-by":"publisher","first-page":"dlab148","DOI":"10.1093\/jacamr\/dlab148","article-title":"Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series","volume":"3","author":"El-Dalati","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"2025021005563097200_CIT0040","doi-asserted-by":"crossref","first-page":"dlac129","DOI":"10.1093\/jacamr\/dlac129","article-title":"Successful use of nafcillin and ceftaroline combination therapy for persistent MSSA bacteraemia and endocarditis: a case series","volume":"5","author":"Warren","year":"2022","journal-title":"JAC Antimicrob Resist"},{"issue":"12","key":"2025021005563097200_CIT0041","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1111\/jocs.16040","article-title":"Cefazolin plus ertapenem and heart transplantation as salvage therapy for refractory LVAD infection due to methicillin-susceptible Staphylococcus aureus: a case series","volume":"36","author":"Cardenas-Alvarez","year":"2021","journal-title":"J Card Surg"},{"key":"2025021005563097200_CIT0042","doi-asserted-by":"publisher","first-page":"6828538","DOI":"10.1155\/2022\/6828538","article-title":"Persistent methicillin-susceptible bacteremia rapidly cleared with cefazolin and ertapenem combination therapy in a patient with COVID-19","volume":"2022","author":"Ilges","year":"2022","journal-title":"Case Rep Infect Dis"},{"issue":"7","key":"2025021005563097200_CIT0043","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1111\/jocs.16491","article-title":"Oxacillin plus ertapenem rapidly clears persistent left ventricular assist device-related methicillin-susceptible Staphylococcus aureus bacteremia","volume":"37","author":"Wilsey","year":"2022","journal-title":"J Card Surg"},{"issue":"1","key":"2025021005563097200_CIT0044","doi-asserted-by":"publisher","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2025021005563097200_CIT0045","doi-asserted-by":"publisher","first-page":"106363","DOI":"10.1016\/j.ijantimicag.2021.106363","article-title":"Clinical outcomes of daptomycin versus anti-staphylococcal beta-lactams in definitive treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"58","author":"Agnello","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"2025021005563097200_CIT0046","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/infdis\/jiv512","article-title":"Reversion from methicillin susceptibility to methicillin resistance in Staphylococcus aureus during treatment of bacteremia","volume":"213","author":"Proulx","year":"2016","journal-title":"J Infect Dis"},{"issue":"9","key":"2025021005563097200_CIT0047","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/cid\/ciz018","article-title":"Impact of \u03b2-lactam and daptomycin combination therapy on clinical outcomes in methicillin-susceptible Staphylococcus aureus bacteremia: a propensity score-matched analysis","volume":"69","author":"Grillo","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2025021005563097200_CIT0048","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1093\/cid\/ciaa1000","article-title":"Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial","volume":"72","author":"Cheng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025021005563097200_CIT0049","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231189888","article-title":"Daptomycin plus oxacillin for persistent methicillin-susceptible Staphylococcus aureus bacteremia","author":"Kufel","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2025021005563097200_CIT0050","doi-asserted-by":"crossref","first-page":"115802","DOI":"10.1016\/j.diagmicrobio.2022.115802","article-title":"The skip phenomenon in Staphylococcus aureus bacteremia: clinical implications","volume":"104","author":"Go","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"2025021005563097200_CIT0051","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"issue":"8","key":"2025021005563097200_CIT0052","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Mir\u00f3","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2025021005563097200_CIT0053","doi-asserted-by":"publisher","first-page":"e0230383","DOI":"10.1371\/journal.pone.0230383","article-title":"Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: a meta-analysis","volume":"15","author":"Ma","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"2025021005563097200_CIT0054","doi-asserted-by":"publisher","first-page":"e01746","DOI":"10.1128\/AAC.01746-18","article-title":"Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections","volume":"63","author":"Zimmerli","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2025021005563097200_CIT0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/antibiotics9020059","article-title":"Bacterial biofilm and its role in the pathogenesis of disease","volume":"9","author":"Vestby","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"2025021005563097200_CIT0056","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1128\/AAC.00740-10","article-title":"Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis","volume":"55","author":"Vergidis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"10121","key":"2025021005563097200_CIT0057","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"2025021005563097200_CIT0058","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1093\/jac\/dkaa144","article-title":"Combination therapy with rifampicin or fosfomycin in patients with Staphylococcus aureus bloodstream infection at high risk for complications or relapse: results of a large prospective observational cohort","volume":"75","author":"Rieg","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2025021005563097200_CIT0059","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2796.2005.01598","article-title":"Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients","volume":"259","author":"Ruotsalainen","year":"2006","journal-title":"J Intern Med"},{"issue":"5","key":"2025021005563097200_CIT0060","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/microorganisms10050848","article-title":"The effectiveness of combination therapy for treating methicillin-susceptible Staphylococcus aureus bacteremia: a systematic literature review and a meta-analysis","volume":"10","author":"Grillo","year":"2022","journal-title":"Microorganisms"},{"key":"2025021005563097200_CIT0061","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2025021005563097200_CIT0062","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2025021005563097200_CIT0063","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijantimicag.2008.04.011","article-title":"Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an emergency department of a medical centre in Taiwan","volume":"32","author":"Liao","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"2025021005563097200_CIT0064","doi-asserted-by":"publisher","first-page":"e1005745","DOI":"10.1371\/journal.pcbi.1005745","article-title":"Modeling antibiotic treatment in hospitals: a systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies","volume":"13","author":"Tepekule","year":"2017","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"2025021005563097200_CIT0065","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3390\/genes6041256","article-title":"Daptomycin-nonsusceptible Staphylococcus aureus: the role of combination therapy with daptomycin and gentamicin","volume":"6","author":"Jiang","year":"2015","journal-title":"Genes (Basel)"},{"key":"2025021005563097200_CIT0066","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/AAC.48.8.2871-2875.2004","article-title":"Synergy of daptomycin with oxacillin and other \u03b2-lactams against methicillin-resistant Staphylococcus aureus","volume":"48","author":"Rand","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2025021005563097200_CIT0067","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1128\/AAC.00047-09","article-title":"Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin","volume":"53","author":"John","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025021005563097200_CIT0068","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1093\/cid\/ciaa1000","article-title":"Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial","volume":"72","author":"Cheng","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2025021005563097200_CIT0069","doi-asserted-by":"publisher","first-page":"ofab476","DOI":"10.1093\/ofid\/ofab476","article-title":"The cost-effectiveness of cefazolin compared with antistaphylococcal penicillins for the treatment of methicillin-sensitive Staphylococcus aureus bacteremia","volume":"8","author":"Pliakos","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 1","key":"2025021005563097200_CIT0070","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/ofid\/ofw172.776","article-title":"Safety and economic benefit of cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus (MSSA) bloodstream infections (BSI)","volume":"3","author":"Flynt","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2025021005563097200_CIT0071","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/cid\/ciy399","article-title":"National costs associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010\u20132014","volume":"68","author":"Klein","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae252\/59225727\/zxae252.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/4\/150\/59225727\/zxae252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/4\/150\/59225727\/zxae252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:56:55Z","timestamp":1739167015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/4\/150\/7749061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":71,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,4]]},"published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae252","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,9,4]]}}}